Informative study designs to identify true parameter–covariate relationships

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2009-03-27

• Fields of study

  Mathematics, Medicine

• Identifiers
  DOI 10.1007/s10928-009-9115-yPMID 19326192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development

  2010cited by this paper
• Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies

  2008cited by this paper
• Model‐based Drug Development

  2007cited by this paper
• Dosing in Obesity: A Simple Solution to a Big Problem

  2007cited by this paper
• Lean bodyweight as a descriptor for propofol clearance

  2007cited by this paper
• Diagnosing Model Diagnostics

  2007cited by this paper
• Quantification of Lean Bodyweight

  2005cited by this paper
• Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation

  2005cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper
• How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

  2005cited by this paper
• Some Considerations on the Design of Population Pharmacokinetic Studies

  2005influential reference
• Compartmental Pharmacokinetics of Dantrolene in Adults: Do Malignant Hyperthermia Association Dosing Guidelines Work?

  2005cited by this paper
• Power, Selection Bias and Predictive Performance of the Population Pharmacokinetic Covariate Model

  2004cited by this paper
• A Standard Weight Descriptor for Dose Adjustment in the Obese Patient

  2004cited by this paper
• Population Pharmacokinetics I: Background, Concepts, and Models

  2004cited by this paper
• Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies

  2004cited by this paper
• Development of a dosing strategy for enoxaparin in obese patients.

  2003cited by this paper
• Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics

  2002cited by this paper
• Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test

  2001cited by this paper
• Assessment of Actual Significance Levels for Covariate Effects in NONMEM

  2001cited by this paper
• Simulation of clinical trials.

  2000cited by this paper
• Automated Covariate Model Building Within NONMEM

  1998cited by this paper
• Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

  1992cited by this paper
• A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam

  1991cited by this paper

• Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants

  2024cites this paper
• New Horizons in the impact of frailty on pharmacokinetics: latest developments.

  2021cites this paper
• Scaling of clearance by body size and composition

  2019cites this paper
• Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects

  2018cites this paper
• Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

  2017influential citation
• The Impact of Model-Misspecification on Model Based Personalised Dosing

  2016cites this paper
• Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects

  2015cites this paper
• A General Purpose Pharmacokinetic Model for Propofol

  2014cites this paper
• Applied Pharmacometrics in the Obese Population

  2014cites this paper
• Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

  2014cites this paper
• Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults

  2012cites this paper
• Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance

  2012cites this paper
• Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib

  2012cites this paper
• A generalisation of T‐optimality for discriminating between competing models with an application to pharmacokinetic studies

  2012cites this paper
• The Relationship between Drug Clearance and Body Size

  2012cites this paper
• Design of pharmacokinetic studies for latent covariates

  2011cites this paper
• Anesthetizing the obese.

  2011cites this paper
• The effects of obesity on drug pharmacokinetics in humans

  2011influential citation
• Pharmacokinetic concepts revisited--basic and applied.

  2011cites this paper